Human Milk Oligosaccharides: Next- Generation Functions and Questions

Editor(s): Lars Bode.

Human Milk Oligosaccharides: Next-Generation Functions and Questions 

Lars Bode 

The past decade has experienced an immense increase in research on human milk oligosaccharides (HMOs), mostly driven by (a) advances in high-throughput glycan analysis and (b) large-scale glycan synthesis as well as (c) the advent of modern microbiome research. 

Advances in high-throughput glycan analysis have enabled the research community to analyze HMO composition in hundreds and sometimes thousands of milk samples from large mother-infant cohorts to investigate associations between maternal factors and HMO com­position as well as between HMO composition and infant outcomes. However, the identified associations cannot prove cause-and-effect rela­tionships. Cohesive and consistent results from suitable preclinical in vitro, tissue culture and animal models, human cohort associations, as well as randomized controlled trials (RCTs) will be required to make con­clusive claims about specific HMO functions. As an example from our own work, we identified a specific HMO called disialyllacto-N-tetraose (DSLNT) that reduces incidence and severity of necrotizing enterocoli-tis (NEC) in a rodent model [1]. While the results are encouraging, the validity of data from available preclinical NEC models in rodents or pig­lets is limited [2]. Animals are exposed to external hypoxic and/or hypo-thermic insults that are rather artificial, and the use of animals itself is a limitation due to interspecies differences in gastrointestinal development, anatomy, and physiology. Thus, advancing a potential therapeutic like DSLNT from controversial preclinical models to clinical treatment trials carries a tremendous risk of failure. However, in parallel, we conducted a multicenter clinical cohort study on 200 mothers and their preterm, very low-birthweight infants that were predominantly human milk-fed and showed that infants who developed NEC received less DSLNT with the milk than infants who did not develop NEC [3]. The latter results do not prove cause-and-effect, but the combination of preclinical testing and human cohort associations raises the confidence towards clinical applica­tion. Future studies in the preclinical model as well as in tissue culture are going to help us elucidate the underlying mechanism, and a carefully designed RCT is going to be needed to ultimately prove the use of DSLNT in NEC prevention. 

Advances in glycan synthesis have made individual HMOs available for research as well as commercial application. Chemoenzymatic synthe­sis is extending our repertoire of available HMOs at smaller scale for in vitro and preclinical research [4]. The help of bioengineered microbes allows the synthesis of individual HMOs at large scale for commercial application [5]. However, knowledge about specific functions and poten­tial adverse effects of individual HMOs remains very limited at best. Human milk contains a personalized mixture of hundred or more dif­ferent and structurally distinct HMOs, which raises questions whether the application of single individual HMOs instead of complex mixtures causes imbalances in infant gut microbial communities or in the infant immune system with potential short- and long-term health consequences. 

Advances in microbiome research and the associated analytical and bioinformatics tools further sparked an interest in HMOs. The compo­sition of microbial communities in the gut and other organs and their metabolic and functional capabilities have been associated with numer­ous conditions, including obesity, inflammatory bowel disease, autism, asthma, and allergies – to only name a few. The concept that HMOs help shape microbial communities early on in life and affect short- and long-term health is indeed striking. Future research is going to apply a combination of preclinical and clinical studies to systematically elucidate HMO structure-function relationships and identify whether individual HMOs like DSLNT or mixtures of HMOs (the way they naturally occur in human milk) provide short- or long-term benefits to infants and poten­tially adults. 

References 

  1. Jantscher-Krenn E, Zherebtsov M, Nissan C, et al: The human milk oligosaccha-
    ride disialyllacto-N-tetraose prevents necrotizing enterocolitis in neonatal rats. Gut 
    2011;61:1417–1425.
  2. Tanner SM, Berryhill TF, Ellenburg JL, et al: Pathogenesis of necrotizing enterocolitis: modeling the innate immune response. Am J Pathol 2015;185:4–16.
  3. Autran CA, Kellman BP, Kim JH, et al: Human milk oligosaccharide composition predicts risk of necrotizing enterocolitis in preterm infants. Gut 2018;67:1064–1070.
  4. Prudden AR, Liu L, Capicciotti CJ, et al: Synthesis of asymmetrical multiantennary 
    human milk oligosaccharides. Proc Natl Acad Sci USA 2017;114:6954–6959.
  5. Bode L, Contractor N, Barile D, et al: Approaches to overcome the limited availability of human milk oligosaccharides: challenges and opportunities for research and appli­cation. Nutr Rev 2016;74:635–644. 

Abstract

Human milk oligosaccharides (HMOs) are the third most abundant component of human milk. So far, more than 150 different and structurally distinct HMOs have been identified. HMO composition varies substantially between women, but remains fairly constant over the course of lactation in the same woman. Which maternal genetic and environmental factors drive the interindividual variations in HMO composition remains poorly understood, and it is currently unknown whether or not a woman’s characteristic HMO composition has evolved to match her own infant’s specific needs. A combination of preclinical, cohort, and clinical studies is required to fully assess the many effects, functions, and potential claims associated with HMOs. In some cases, individual HMOs exert a certain effect and, while there might be some redundancy, the effects are often highly structure-specific. In other cases, a combination of different HMOs in specific ratios to each other is required to be effective, and future research needs to assess whether or not the administration of individual HMOs alone may be counterproductive and potentially harmful to the infant’s short- and long-term health. Overall, the personalized complexity of HMOs cannot be mimicked in artificial infant formula and provides yet another powerful reason to protect, promote, and support breastfeeding.

What Are Human Milk Oligosaccharides?


One liter of mature human milk contains 5–15 g of complex carbohydrates that are collectively called human milk oligosaccharides (HMOs). Their high concentration makes HMOs the third most abundant solid component of mature milk, only exceeded by the concentration of lactose and total lipids and often exceeding the concentration of total proteins [1]. In comparison, the concentration of oligosaccharides in bovine milk is 100- to 1,000-fold lower, and many of the bovine milk oligosaccharides are structurally distinct from and less complex than HMOs. While more than 150 different HMOs have been identified so far, their composition follows a basic blueprint that connects the five building blocks glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc), and N-acetylneuraminic acid (Neu5Ac) in specific linkages (Fig. 1a) [2]. All HMOs carry lactose (Galβ1–4Glc) at the reducing end. Lactose can be elon- gated in the C3 position of Gal with either lacto-N-biose (Galβ1–3GlcNAc, type 1 chain) or N-acetyllactosamine (Galβ1–4GlcNAc, type 2 chain) (Fig. 1b). This ostensibly minor difference in the linkage between Gal and GlcNAc might be important for HMO digestion and bioavailability. While the β1–3 linkage in lacto-N-biose(type 1) cannotbecleavedbytheinfant’sintestinalβ-galactosidase (lactase), the β1–4-linkage in N-acetyllactosamine (type 2) is likely a substrate for the enzyme, suggesting that type 2 chain HMOs like lacto-N-neotetraose (LNnT) are partially digested in the infant’s proximal small intestine, do not reach the infant’s distal small intestine and colon intact, and are therefore not available for absorption or microbial utilization. In contrast, type 1 chain HMOs like lacto-N-tetraose (LNT) cannot be cleaved by lactase, resist degradation in the infant’s small intestine, reach the colon intact, and are available for absorption or microbial utilization. In addition to chain elongation at the C3 position of Gal, the disaccharides lacto-N-biose or N-acetyllactosamine can also be add- ed at the C6 position of Gal, leading to chain branching (Fig. 1c). The repeated addition of disaccharides to the growing chain leads to more complex linear or branched HMOs (Fig. 1d). Moreover, HMOs can be modified by the addition of Fuc in α1–2, α1–3, and/or α1–4 linkage and/or the addition of Neu5Ac in α2–3 and/or α2–6 linkage. Each Neu5Ac contains a carboxyl group and intro- duces a negative charge to an HMO. Fuc or Neu5Ac can be added to lactose to yield the small HMO trisaccharides 2′-fucosyllactose (2′FL), 3-fucosyllactose (3FL), 3′-sialyllactose, or 6′-sialyllactose (Fig. 1e). One or more Fuc and/or Neu5Ac can also be added to the growing linear or branched HMO chain to form complex HMOs with potentially multiple negative charges if more than one Neu5Ac are added (Fig. 1f). Neu5Ac-containing HMOs are often referred to as “acidic” HMOs.
Although HMO composition follows a basic blueprint and more than 150 different HMOs have been identified so far, it is important to note that every woman synthesizes and secretes a distinct HMO composition profile that varies substantially between different women, but remains fairly constant over the course of lactation for the same woman.

Human milk oligosaccharide (HMO) blueprint and structural diversity.

Fig. 1. Human milk oligosaccharide (HMO) blueprint and structural diversity. HMOs consist of the five monosaccharide building blocks glucose (black circles), galactose (Gal, grey circles), N-acetylglucosamine (squares), fucose (Fuc, triangles), and N-acetylneuraminic acid (NeuAc, diamonds). a The HMO structural composition follows a basic blueprint. b Lactose forms the reducing end and can be elongated in the C3 or C6 position of Gal with either  lacto-N-biose  to  form  type  1  chains  or  with  N-acetyllactosamine  to  form  type 2 chains. While the β1–3 linkage in lacto-N-biose (type 1) cannot be cleaved by the infant’s intestinal β-galactosidase (lactase), the β1–4 linkage in N-acetyllactosamine (type 2) is likely a substrate for the enzyme (indicated by scissors), suggesting that type 2 chain  HMOs like lacto-N-neotetraose are partially digested in the infant’s small intestine and are thus not available in their intact form for absorption or microbial utilization. c Addition of either of the two disaccharides in β1–6 linkage leads to HMO branching. d The repeated addition of disaccharides to the growing chain leads to more complex linear or branched HMOs. e, f Lactose (e) or the elongated or branched chains (f) can be modified with Fuc in α1–2, α1–3, or α1–4 linkage to yield fucosylated HMOs. Lactose or the elongated or branched chains can also be modified with NeuAc in α2–3 or α2–6 linkage to yield sialylated HMOs, occasionally also referred to as “acidic HMOs.” Some examples of the diverse collection of HMOs are provided.

What Drives the Variation in HMO Composition?


Some of the variation in HMO composition can be explained by maternal genetics [1]. HMO fucosylation is mainly catalyzed by two different fucosyltransferases, enzymes that facilitate the addition of Fuc to the HMO backbone in different linkages [3, 4]. Fucosyltransferase 2 (FUT2) adds Fuc to Gal in an α1–2 linkage [5]. Mutations in the Secretor gene, which encodes FUT2, lead to an inactivation of the enzyme, and, as a consequence, milk samples of so called nonsecretor women have very low concentrations of α1–2-fucosylated HMOs, e.g.2′-FL or lacto-N-fucopentaose 1 (LNFP1). Fucosyltransferase 3 (FUT3) adds Fuc to Gal or GlcNAc in an α1–3 or α1–4linkage, depending on whether the substrate is a type 1 or type 2 HMO chain [6]. Mutations in the Lewis gene, which encodes FUT3, lead to an inactivation of the enzyme, and, as a consequence, milk samples of so called Lewis-negative women have very low concentrations of α1–3/4-fucosylated HMOs. The permutation of active/inactive FUT2 and FUT3 enzymes leads to four distinct HMO groups [4]: (a) Lewis- positive secretors (FUT2 and FUT 3 active), (b) Lewis-positive nonsecretors (FUT2 inactive, but FUT3 active), (c) Lewis-negative secretors (FUT2 active, but FUT3 inactive), and (d) Lewis-negative nonsecretors (both FUT2 and FUT3 inactive). These four groups can be distinguished by the presence or near absence of specific fucosylated HMOs, which is almost an all-or-nothing phenomenon. For example, 2′FL is either present and one of the dominant HMOs in the milk of secretor women (active FUT2), or it is almost completely absent in the milk of nonsecretor women (inactive FUT2). In contrast, the variation of HMOs that do not depend on FUT2 or FUT3 activity is subtler. In fact, it remains poorly understood which enzymes other than FUT2 and FUT3 are involved in HMO biosynthesis in the human mammary gland epithelial cell.
In addition to maternal genetics and potentially epigenetics, maternal environmental factors may also affect HMO composition. Our recent work with mice has shown that milk oligosaccharide concentrations decrease when lactating dams are fed a high-fat diet and increase when dams are exercising [unpubl. data]. How diet, exercise, and other lifestyle factors impact HMO composition in humans is currently under investigation. Maternal health may also affect HMO composition. Initial preliminary data suggest that obesity or chronic inflammatory diseases impact HMO composition [unpubl. data]. In addition, cross-sectional data from the Canadian Healthy Infant Longitudinal Development (CHILD) national birth cohort [7] indicate that parity increases overall HMO concentration, but maternal age, method of delivery, or infant gender showed no association with HMO composition [unpubl. data].

What Happens to HMOs after Ingestion?


Once ingested, HMOs resist the low stomach pH as well as degradation through pancreatic and brush border enzymes in the small intestine [8, 9], with the potential exception of type 2 chains in which the terminal β1–4-linked Gal may be cleaved off by the enzyme lactase. Approximately 1% of the ingested HMOs are absorbed and can be measured in the systemic circulation as well as in the urine [10–13], indicating that HMO effects extend to tissues and organs other than the intestine. Most HMOs reach the distal small intestine and colon intact where they are either metabolized by microbes or excreted with the feces.

What Are Potential HMO Functions?


HMOs serve as metabolic substrates for specific and potentially health-promoting bacteria in the infant’s intestine [14–16], making them the first prebiotics that humans are exposed to in life – when the infant is breastfed (A, Fig. 2). How- ever, recent data from ex vivo studies suggest that the prebiotic effects of differ- ent HMOs are not interchangeable and are indeed structure-specific [unpubl. data]. The composition of microbial communities isolated from infant fecal samples and cultured under anaerobic conditions changes over time depending on what specific HMOs are added to the culture. For example, the composition of a microbial community looks very different when exposed to either a mixture of HMOs that were isolated from pooled human milk or to individual HMOs like 2′FL or LNT. Since the differential composition and activity of microbial communities has been linked to diseases like obesity, diabetes, inflammatory bowel disease or autism, exposing infants to individual HMOs in formula in- stead of a complex HMO mixture in human milk may increase disease risks. Long-term follow-up studies are required to rule out this potential risk and avoid potential harm to the infant’s short- and long-term  health.
However, HMOs are more than just “food for bugs.” HMOs can have direct bacteriostatic or bacteriocidal antimicrobial effects (B, Fig. 2). For example, HMOs halt the growth of Streptococcus agalactiae (group B Streptococcus; GBS) [17], a leading cause of invasive bacterial infections in newborns, typically acquired vertically during childbirth secondary to maternal vaginal colonization. GBS transmission to the newborn is associated with risk of pneumonia, septicemia, and meningitis [18–20]. Multidimensional chromatography revealed that the bacteriostatic effect is structure dependent and that LNT is most effective. GBS transposon mutant library screening identified a GBS glycosyltransferase as the HMO target. Most intriguingly, the effects of HMOs synergize with common antibiotics like vancomycin and ciprofloxacin, with high relevance to the emerging antibiotic resistance crisis [17].
HMOs also have antiadhesive effects (C, Fig. 2). Many pathogens need to attach to epithelial surfaces in order to proliferate and potentially invade host tissues. The attachment is often facilitated by pathogen surface molecules that bind to glycan structures on the epithelial cell surface, also known as the glycocalyx. HMOs and glycans on epithelial cell surfaces share many structural features, allowing HMOs to mimic epithelial surface glycans and serve as soluble decoy receptors. Instead of pathogens binding to epithelial surfaces and causing disease, they bind to the soluble HMO decoys and are washed out without attaching and without causing disease. Examples for antiadhesive effects of HMOs include bacterial pathogens like Campylobacter jejuni [21] or enteropathogenic Escherichia coli [22] as well as protozoan parasites like Entamoeba histolytica [23].
HMOs may also have direct effects on epithelial cells, independent of, but indirectly affecting microbes (D, Fig. 2). For example, bladder epithelial cells that had been exposed to HMOs are significantly more resistant to uropathogenic E. coli invasion and cytotoxicity [24]. HMOs may also alter immune cell responses, either locally in the gut or systemically (E, Fig. 2).
In conclusion, there are indirect effects of HMOs on the infant that are mediated through changes in microbial communities, e.g. by serving as prebiotics, antimicrobials, or antiadhesives, and there are direct effects on the infant, e.g. by modulating epithelial or immune cell responses. In addition, there may be multiple other mechanisms of HMO action that have not yet been discovered. Over- all, the arsenal of HMO effects is likely relevant in a variety of health and disease contexts.

Potential effects of human milk oligosaccharides (HMOs) at the host-microbe in- terface

Fig. 2. Potential effects of human milk oligosaccharides (HMOs) at the host-microbe interface. HMOs affect the infant indirectly through changes in microbial communities, e.g. by serving as prebiotics (a), antimicrobials (b), or antiadhesives (c), or directly, e.g. by modulating epithelial (d) or immune cell responses (e).

How Do We Interrogate the Effects of HMOs?


Accumulating data from tissue culture, animal, or human cohort studies suggest that HMOs benefit the human milk-fed infant. However, results from many of these studies raise additional questions. How relevant are results generated from in vitro or animal models? How similar are cell lines in culture compared to tissues in the infant body? How comparable are animal models to human anatomy, physiology, and pathophysiology? How meaningful are associations between HMOs and infant outcome measures in human cohort studies? Are the observed associations true cause-and-effect relationships? No one single study alone will likely provide a comprehensive answer. Instead, a thoroughly designed inter- rogative strategy that combines preclinical studies in tissue culture and animal models with clinical cohort analyses and eventually clinical intervention studies will be required to fully assess the many effects, functions, and potentials claims associated with HMOs. Our recent work on necrotizing enterocolitis (NEC) serves as one example of how the combination of preclinical studies and human cohort studies can inform clinical intervention studies to test the hypothesis that HMOs contribute to the beneficial effect of human milk feeding.
NEC is one of the most common and fatal gastrointestinal disorders in preterm infants [25]. About 5% of all very-low-birthweight (VLBW) infants develop NEC, with a mortality rate of over 25%. While formula-fed infants are at a 6- to 10-fold higher risk to develop NEC [26], the protective mechanisms of feeding human milk remain poorly understood. In contrast to formula, human milk is an abundant source of HMOs. In addition, the NEC-preventing effect of human donor milk persists even after pasteurization, a process that destroys and inactivates many human milk bioactives, but keeps HMOs intact and active.
Based on these observations, we hypothesized that HMOs contribute to the lower NEC incidence in human milk-fed infants, and tested the hypothesis in a neonatal rat model [27]. Newborn rat pups were either left with the dam to serve as “breastfed” control or removed from the dam and received formula by oral gavage. While all of the dam-fed pups survived the first 4 days of life, only ∼75% of the formula-fed pups survived. However, 95% of the pups survived when they received a formula that was supplemented with HMOs that were isolated from pooled human milk. This significant increase in survival coincided with decreased pathological observations, both macroscopically as well as microscopically. We then applied a multidimensional chromatography approach to separate the different HMOs first by charge and later by size, and identified one specific HMO, disialyllacto-N-tetraose (DSLNT), which contains two Neu5Ac, to be responsible for the beneficial effects. Enzymatic removal of just one of the Neu5Ac led to a complete loss of function, indicating that the effect is highly structure-specific [27].
While the data were encouraging, the validity of available preclinical NEC models in rodents or piglets is limited [28]. Animals are exposed to external hypoxic and/or hypothermic insults that are rather artificial, and the use of animals itself is a limitation due to interspecies differences in gastrointestinal development, anatomy, and physiology. Thus, advancing a potential therapeutic like DSLNT from controversial preclinical models to clinical treatment trials carried a tremendous risk of failure. To help close the gap between animal models and clinical intervention studies, we used an intermediate approach and conducted a multicenter clinical prospective cohort study with mothers and their VLBW infants fed predominantly human milk [29]. The study was based on the observation that some infants still develop NEC despite receiving predominantly human milk. Since HMO composition varies between women, it led us to hypothesize that infants who develop NEC received milk with less DSLNT than infants who do not develop NEC. We recruited 200 mothers and their VLBW infants that were predominantly human milk-fed. We analyzed HMO composition in human milk fed to infants over the first 28 days postpartum, matched each NEC case with 5 controls, and used logistic regression and generalized estimating equation to show that DSLNT concentrations were significantly lower in almost all milk samples in all 8 NEC cases when compared to controls. In fact, DSLNT abundance could identify NEC cases prior to onset. Aggregate assessment of DSLNT over multiple days enhanced the separation of NEC cases and control subjects, making DSLNT content in human milk a potential noninvasive mark- er to identify infants at risk of developing NEC. While the cohort association data alone would raise questions about cause-and-effect, the combination with data from the preclinical model substantially increases the confidence that the observed effects are indeed due to DSLNT, lowering the risk threshold for a clinical intervention study to fail.
Overall, the NEC project is an example of how the combination of preclinical data and clinical cohort data can inform clinical intervention studies (Fig. 3). A similar approach has been used in the past to relate HMOs to a reduction of C. jejuni infection and diarrhea [21, 30] and is currently used to study the effects of HMOs on infant body composition and childhood obesity risk as well as on allergies and asthma risk.
What we have learnt so far from this combined approach is that sometimes specific HMOs are effective and those effects are usually highly structure-specific and dose-dependent. The underlying mechanisms are likely mediated by specific receptors on host (infant) tissues or on microbes. In other cases, a combination of different HMOs in specific ratios to each other is required to be effective. The underlying mechanisms are likely mediated indirectly through shaping microbial communities or directly through a coordinated interaction of different HMOs with multiple different receptors or even different cell types, for ex- ample in the immune system. In situations where relative abundances of many different HMOs matter more than individual HMOs alone, it raises the question whether or not a woman’s characteristic HMO composition has evolved to match her own infant’s specific needs. In that case, HMOs can be seen as an- other example of personalized nutrition early on in life, which comes in addition to other personalized components of human milk like antibodies, milk microbiota, immune cells, and progenitor cells. In fact, the personalized complexity of HMOs provides yet another powerful reason to protect, promote, and support breastfeeding.

Combining preclinical studies and human cohort studies to inform clinical inter- vention studies with the goal to investigate human milk oligosaccharide (HMO) functions.

Fig. 3. Combining preclinical studies and human cohort studies to inform clinical inter- vention studies with the goal to investigate human milk oligosaccharide (HMO) functions. Necrotizing enterocolitis (NEC) is one example of how a combination of preclinical studies and human cohort studies led to the identification one specific HMO with potential benefits for infant health. Clinical observations led to the hypothesis that HMOs contribute to a lower risk for preterm infants to develop NEC when they are given human milk. The pre-clinical model in neonatal rats confirmed the hypothesis and also identified one specific HMO that was most effective in reducing pathology. HMO analysis in milk that was fed to human preterm infants revealed associations between HMO composition and NEC and matching the preclinical data. The same HMO that was protective in the neonatal rat model was found in significantly lower concentration in milk fed to infants who developed NEC compared to control infants who did not develop NEC. The combined results from preclinical studies and human cohort studies identified one specific HMO that is likely responsible for the protective effect and informed clinical intervention studies. Continued work in preclinical models is going to help elucidate the underlying mechanism.

References

  • 1 Bode L: Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 2012;22:1147–1162.
  • 2 Kobata A: Structures and application of oligosaccharides in human milk. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:731–747.
  • 3 Chaturvedi P, Warren CD, Altaye M, et al: Fucosylated human milk oligosaccharides vary between individuals and over the course oflactation.Glycobiology 2001;11:365–372.
  • 4 Stahl B, Thurl S, Henker J, et al: Detection of four human milk groups with respect to Lew- is-blood-group-dependent oligosaccharides by serologic and chromatographic analysis. Adv Exp Med Biol 2001;501:299–306.
  • 5 Kumazaki T, Yoshida A: Biochemical evidence that secretor gene, Se, is a structural gene encoding a specific fucosyltransferase. Proc Natl Acad Sci USA 1984;81:4193–4197.
  • 6 Johnson PH, Watkins WM: Purification of the Lewis blood-group gene associated α-3/4- fucosyltransferase from human milk: an enzyme transferring fucose primarily to type 1 and lactose-based oligosaccharide chains. Glycoconj J 1992;9:241–249.
  • 7 Subbarao P, Anand SS, Becker AB, et al: The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining develop- mental origins of allergy and asthma. Thorax 2015;70:998–1000.
  • 8 Gnoth MJ, Kunz C, Kinne-Saffran E, Rudloff S: Human milk oligosaccharides are minimally digested in vitro. J Nutr 2000;130: 3014–3020.
  • 9 Engfer MB, Stahl B, Finke B, et al: Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am J Clin Nutr 2000;71:1589–1596.
  • 10 Ruhaak LR, Stroble C, Underwood MA, Lebrilla CB: Detection of milk oligosaccharides in plasma of infants. Anal Bioanal Chem 2014;406:5775–5784.
  • 11 Goehring KC, Kennedy AD, Prieto PA, Buck RH: Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. PLoS One 2014; 9:e101692.
  • 12 Rudloff S, Obermeier S, Borsch C, et al: In- corporation of orally applied (13)C-galactose into milk lactose and oligosaccharides. Glycobiology 2006;16:477–487.
  • 13 Dotz V, Rudloff S, Blank D, et al: 13C-labeled oligosaccharides in breastfed infants’ urine: individual-, structure- and time-dependent differences in the excretion. Glycobiology 2014;24:185–194.
  • 14 German JB, Freeman SL, Lebrilla CB, Mills DA: Human milk oligosaccharides: evolution, structures and bioselectivity as substrates for intestinal bacteria. Nestle Nutr Workshop Ser Pediatr Program 2008;62:205– 218.
  • 15 Sela DA, Chapman J, Adeuya A, et al: The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci USA 2008;105:18964– 18969.
  •  16 Marcobal A, Barboza M, Sonnenburg ED, et al: Bacteroides in the infant gut consume milk oligosaccharides via mucusutilization pathways. Cell Host Microbe 2011;10:507– 514.
  • 17 Lin AE, Autran CA, Szyszka A, et al: Human milk oligosaccharides inhibit growth of group B Streptococcus. J Biol Chem 2017;292: 11243–11249.
  •  18 Edwards MS: Issues of antimicrobial resistance in group B Streptococcus in the era of intrapartum antibiotic prophylaxis. Semin Pediatr Infect Dis 2006;17:149–152.
  •  19 Heath PT, Schuchat A: Perinatal group B streptococcal disease. Best Pract Res Clin Ob- stetGynaecol 2007;21:411–424.
  • 20 Thigpen MC, Whitney CG, Messonnier NE, et al: Bacterial meningitis in the United States, 1998–2007. N Engl J Med 2011;364: 2016–2025.
  • 21 Ruiz-Palacios GM, Cervantes LE, Ramos P, et al: Campylobacter jejuni binds intestinal H(O) antigen (Fucα1,2Galβ1,4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 2003; 278:14112–14120.
  •  22 Manthey CF, Autran CA, Eckmann L, Bode L: Human milk oligosaccharides protect against enteropathogenic E. coli attachment in vitro and colonization in suckling mice. J Pediatr Gastroenterol Nutr 2014;58:167–170.
  • 23 Jantscher-Krenn E, Lauwaet T, Bliss LA, et al: Human milk oligosaccharides reduce Ent- amoeba histolytica attachment and cytotoxicity in vitro. Br J Nutr 2012;108:1839–1846.
  •  24 Lin AE, Autran CA, Espanola SD, et al: Human milk oligosaccharides protect bladder epithelial cells against uropathogenic Escherichia coli invasion and cytotoxicity. J Infect Dis 2014;209:389–398.
  •  25 Neu J, Walker WA: Necrotizing enterocolitis. N Engl J Med 2011;364:255–264.
  • 26 Lucas A, Cole TJ: Breast milk and neonatal necrotising enterocolitis. Lancet 1990;336: 1519–1523.
  • 27 Jantscher-Krenn E, Zherebtsov M, Nissan C, et al: The human milk oligosaccharides disialyllacotse-N-tetraose prevents necrotizing enterocolitis in neonatal rats. Gut 2012;61: 1417–1425.
  • 28 Tanner SM, Berryhill TF, Ellenburg JL, et al: Pathogenesis of necrotizing enterocolitis: modeling the innate immune response. Am J Pathol 2015;185:4–16.
  • 29 Autran CA, Kellman BP, Kim JH, et al: Human milk oligosaccharide composition predicts risk of necrotising enterocolitis in pre-term infants. Gut 2018;67:1064–1070.
  • 30 Morrow AL, Ruiz-Palacios GM, Altaye M, et al: Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr 2004;145:297– 303.